Replies to post #163077 on Biotech Values

[DewDiligence]

PTLA starts phase-2 trial of Andexanet Alfa (f/k/a PRT4445) as an antidote to Daiichi Sankyo’s Edoxaban:

http://finance.yahoo.com/news/portola-pharmaceuticals-initiates-phase-2-120000764.html

This trial took a long time to get fired up insofar as PTLA’s collaboration with Daiichi Sankyo was announced 9 months ago (#msg-89410130).